Lee's Pharmaceutical
李氏大药厂
Executive Summary
Lee's Pharmaceutical is a Hong Kong-listed Chinese pharmaceutical company with a focus on specialty pharmaceuticals and oncology therapeutics. The company has historically been active in licensing deals and has a growing pipeline of both in-licensed and self-developed assets. With clear BIOSECURE status and Hong Kong domicile, Lee's presents lower regulatory risk for US partnerships compared to mainland Chinese entities. Limited public information on current pipeline and recent activities suggests the need for direct engagement to assess current deal opportunities.
Structure: Lee's Pharmaceutical is structured as a Hong Kong-listed entity, which typically provides more straightforward due diligence compared to VIE structures common among mainland Chinese companies. The Hong Kong listing and domicile generally offer better regulatory transparency and corporate governance standards. However, the company likely has significant operational presence in mainland China through subsidiaries.
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, with Hong Kong domicile providing additional regulatory buffer
Key Exposures:
- •Potential mainland China manufacturing operations
- •Supply chain dependencies in China
Mitigation: Hong Kong listing and domicile provide natural mitigation; specific BIOSECURE compliance measures unknown due to limited public information
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity publicly available - requires direct outreach to assess current opportunities
Approach: Direct engagement with senior BD leadership recommended to assess current pipeline assets and out-licensing opportunities, particularly given clear BIOSECURE status
Red Flags
- ⚠Limited public disclosure on current pipeline and activities
- ⚠Lack of recent corporate event information may indicate reduced activity or poor investor relations
- ⚠Absence of key personnel information complicates relationship mapping
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.